



(51) International Patent Classification:

C07D 491/107 (2006.01) **C07D 401/04** (2006.01)
A61K 31/4184 (2006.01) **C07D 235/02** (2006.01)
A61K 31/4188 (2006.01) **C07D 401/12** (2006.01)
A61K 31/4439 (2006.01) **C07D 403/12** (2006.01)
A61K 31/506 (2006.01) **C07D 405/12** (2006.01)
A61P 25/28 (2006.01) **C07D 491/20** (2006.01)

(21) International Application Number:

PCT/SE2011/051555

(22) International Filing Date:

21 December 2011 (21.12.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/425,852 22 December 2010 (22.12.2010) US
 61/529,620 31 August 2011 (31.08.2011) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors; and


(75) Inventors/Applicants (for US only): CSJERNYIK, Gabor [HU/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **KARLSTRÖM, Sofia** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **KERS, Annika** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **KOLMODIN, Karin** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **NYLÖF, Martin** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **ÖHBERG, Liselotte** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **RAKOS, Laszlo** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **SANDBERG, Lars** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **SEHGELMEBLE, Fernando** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **SÖDERMAN, Peter** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **SWAHN, Britt-Marie** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **VON BERG, Stefan** [DE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).


[Continued on next page]

(54) Title: COMPOUNDS AND THEIR USE AS BACE INHIBITORS

FIG. 1A



(57) Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A β -related pathologies such as Down's syndrome, β - amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.





(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))